NCT01455493已完成2 期
A Multicenter, Single-Arm, Open-Label, Phase II Study of GDC-0980 for The Treatment of Recurrent or Persistent Endometrial Carcinoma
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 56
- 主要终点
- Progression-free survival (PFS), defined as the time from the first GDC-0980 treatment to disease progression as assessed by the investigator using RECIST v1.1, or death from any cause while on study
研究概览
简要总结
This is a multicenter, single-arm, open-label Phase II study to evaluate the activity of GDC-0980 in patients with recurrent or persistent endometrial cancer. The safety, tolerability, and pharmacokinetics of GDC-0980 will also be evaluated.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- Female
- 接受健康志愿者
- 否
入选标准
- •Patients must have recurrent or persistent endometrial carcinoma that is refractory to curative therapy or established treatments
- •Histologic confirmation of the original primary tumor is required
- •Histologic or cytologic confirmation of the recurrent/progressive disease is desired
- •Patients must have had at least one but no more than two prior chemotherapeutic regimens for management of endometrial carcinoma
- •Disease that is measurable per RECIST v1.1
- •No active infection requiring antibiotics
- •Any hormonal therapy directed at the malignant tumor must be discontinued at least 2 weeks prior to first study treatment
- •Any other prior therapy directed at the malignant tumor, including immunologic agents and radiotherapy, must be discontinued at least 2 weeks prior to first study treatment
- •Adequate hematologic and end organ function
排除标准
- •Type I diabetes or Type II diabetes requiring insulin
- •Prior use of mTOR/PI3K inhibitor
- •Current dyspnea at rest or any requirement for supplemental oxygen therapy to perform activities of daily living
- •Previous diagnosis of pulmonary fibrosis of any cause
- •History of myocardial infarction or unstable angina within 6 months prior to first study treatment
- •Congestive heart failure
- •History of malabsorption syndrome or other condition that would interfere with enteral absorption
- •Clinically significant history of liver disease, including cirrhosis and current alcohol abuse
- •Presence of positive test results for hepatitis B or hepatitis C
- •Known HIV infection
- •Active autoimmune disease that is not controlled by nonsteroidal anti inflammatory drugs
- •Need for current chronic corticosteroid therapy
- •Pregnancy, lactation, or breastfeeding
- •Current severe, uncontrolled systemic disease
- •Major surgical procedure or significant traumatic injury within 28 days prior to Day 1 or anticipation of the need for major surgery during the course of study treatment
- •Uncontrolled hypercalcemia
- •Leptomeningeal disease as a manifestation of cancer
- •Known untreated or active brain metastases
- •Grade >=2 hypercholesterolemia or hypertriglyceridemia
研究组 & 干预措施
A
Experimental
干预措施: GDC-0980 (Drug)
结局指标
主要结局
Progression-free survival (PFS), defined as the time from the first GDC-0980 treatment to disease progression as assessed by the investigator using RECIST v1.1, or death from any cause while on study
时间窗: at 6 months
Objective tumor response as assessed by the investigator using RECIST v1.1
时间窗: up to approximately 23 months
次要结局
- Incidence of adverse events(up to approximately 23 months)
- Nature of adverse events(up to approximately 23 months)
- Overall survival (OS), defined as the time from treatment initiation until death from any cause(up to approximately 36 months)
- Duration of objective tumor response defined as the time from first observation of an objective tumor response until first observation of disease progression as assessed by the investigator using RECIST v1.1(up to approximately 23 months)
- Severity of adverse events(up to approximately 23 months)
研究者
相似试验
终止
1 期
A Study of GDC-0810 Single Agent or in Combination With Palbociclib and/or a Luteinizing Hormone-Releasing Hormone (LHRH) Agonist in Women With Locally Advanced or Metastatic Estrogen Receptor Positive Breast CancerBreast CancerNCT01823835Genentech, Inc.152
进行中（未招募）
2 期
A Study to Determine the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of AG-348 in Adult Participants With Non-transfusion-dependent ThalassemiaThalassemiaNCT03692052Agios Pharmaceuticals, Inc.20
Unknown
2 期
Study of HA121-28 in Patients With Non-Small Cell Lung CancerNSCLCNCT05117658CSPC ZhongQi Pharmaceutical Technology Co., Ltd.83
已完成
2 期
A Study of AK104, a PD-1/CTLA-4 Bispecific Antibody in Subjects With Recurrent/Metastatic Cervical CancerRecurrent Cervical CancerMetastatic Cervical CancerNCT04380805Akeso30
招募中
2 期
Safety and Efficacy Study of Zamtocabtagene Autoleucel (MB-CART2019.1) in Pediatric Patients With R/R B-Cell NeoplasmsB-Cell NeoplasmNCT06508931Miltenyi Biomedicine GmbH31